Abstract
A new guideline for mitigating indoor airborne transmission of COVID-19 prescribes a limit on the time spent in a shared space with an infected individual (Bazant and Bush, 2021). Here, we rephrase this safety guideline in terms of occupancy time and mean exhaled carbon dioxide concentration in an indoor space, thereby enabling the use of CO2 monitors in the risk assessment of airborne transmission of respiratory diseases. While CO2 concentration is related to airborne pathogen concentration (Rudnick and Milton, 2003), the guideline developed here accounts for the different physical processes affecting their evolution, such as enhanced pathogen production from vocal activity and pathogen removal via face-mask use, filtration, sedimentation and deactivation. Critically, transmission risk depends on the total infectious dose, so necessarily depends on both the pathogen concentration and exposure time. The transmission risk is also modulated by the fractions of susceptible, infected and immune persons within a population, which evolve as the pandemic runs its course. A mathematical model is developed that enables a prediction of airborne transmission risk from real-time CO2 measurements. Illustrative examples of implementing our guideline are presented using data from CO2 monitoring in university classrooms and office spaces.
Impact Statement
Impact Statement There is mounting scientific evidence that COVID-19 is primarily transmitted through indoor airborne transmission, as arises when a susceptible person inhales virus-laden aerosol droplets exhaled by an infectious person. A safety guideline to limit indoor airborne transmission (Bazant and Bush, 2021) has recently been derived that complements the public health guidelines on surface cleaning and social distancing. We here recast this safety guideline in terms of total inhaled carbon dioxide, as can be readily monitored in most indoor spaces. Our approach paves the way for optimizing air handling systems by balancing health and financial concerns, informs policy for safely re-opening schools and businesses as the pandemic runs its course, and may be applied quite generally in the mitigation of airborne respiratory illnesses, including influenza.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
There was no funding for this work.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
There is no ethics committee approval required for this article.
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
Expanded discussion of the assumptions and results.
Data Availability
The data presented in the article is available upon request.
